|Articles|March 15, 2002
Therapeutic index 'low': AMD treatment feasible, but Santen pulls out
Salt Lake City-IOMED Inc. and Santen Pharmaceuticals Co. said they have ended a joint development agreement intended to launch a noninvasive ophthalmic drug delivery system to provide an anti-angiogenic drug to the retina and choroid in therapeutic quantities.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























